CBD and emerging therapies offer hope for severe childhood epilepsy

Dravet syndrome is a severe, early-onset form of epilepsy characterized by difficult-to-control seizures and serious neurodevelopmental complications. This comprehensive review examines the current landscape of treatments for this devastating condition, with particular attention to both established and emerging therapies. While valproate-based medications remain the cornerstone of treatment, the paper emphasizes that successful management extends beyond seizure control to address the broader neurological and systemic health challenges that accompany the disorder, including developmental delays and other comorbidities.

Among the therapies discussed, cannabidiol (CBD) stands out as one of the most strongly evidence-supported treatments for Dravet syndrome, alongside stiripentol, clobazam, and fenfluramine. The review highlights that many alternative or less commonly used medications—including perampanel, topiramate, levetiracetam, cenobamate, and ketogenic dietary therapy—may benefit specific patients but come with variable efficacy and safety concerns that require careful monitoring. This underscores the importance of understanding how these drugs interact with one another and with individual patient characteristics.

The paper emphasizes that managing Dravet syndrome requires individualized, dynamic treatment strategies rather than one-size-fits-all approaches. Safety profiles, drug interactions, and practical dosing considerations are critical factors that clinicians must weigh when selecting therapies. While emerging genetic and targeted pharmacological therapies offer promise for future disease modification beyond symptomatic seizure control, their clinical impact remains uncertain. The review calls for careful long-term evaluation of these innovative approaches as they move from experimental use into clinical practice.